World News

The AI-powered system automatically analyzes computed tomography (CT) scans that were originally performed for unrelated medical reasons, identifying osteoporotic pathological signs without requiring additional examinations.

Amplifai Health’s acceptance into this programme validates the company’s approach to implementing AI technology in practical healthcare settings where it can make an immediate difference in patient care.

Through this acquisition, Mirum gains worldwide rights to brelovitug, a monoclonal antibody that has advanced to Phase III clinical development.

The 22 national standards, which include two pre-standards developed in 2024, specifically address the safe deployment of AI technologies in medical environments.

The partnership between these companies stems from a late 2024 licensing agreement in which Corxel obtained worldwide rights to CX11, excluding China, from Vincentage.

The merger has already cleared several regulatory hurdles, having secured approval from the Competition Commission of India (CCI) and received ‘No Objection’ letters from the Stock Exchanges.

The grant will enable Qure.ai to develop a comprehensive open-source multi-modal database designed to accelerate future prevention and identification innovations.

The approval specifically targets patients who have already undergone one prior trastuzumab-based treatment regimen.

BMS will pay up to USD850 million, structured as USD50 million in upfront and near-term payments combined with USD800 million in regulatory, development, and milestone-based payouts.

The newly developed syringe has been specifically engineered to work seamlessly with Ypsomed’s YpsoMate 5.5 autoinjector platform.